LLY compared with PRLD: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

PRLDPrelude Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

PRLD: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

LLY, solidPRLD, dashed

LLYELI Lilly & Co

1,407.25· pre 1,424.40· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

PRLDPrelude Therapeutics Inc

3.84· pre 3.78· delayed

Pre-marketNov 4 '26delayed

Mkt cap$306.4MRevenue$6MQ2 FY26Revenue—

Compare

Pre-marketNov 4 '26delayed

LLYELI Lilly & Co

PRLDPrelude Therapeutics Inc

1,407.25pre 1,424.40delayed

Price

3.84pre 3.78delayed

$1.3T

Mkt cap

$306.4M

Q3 FY26$24.4B

Revenue

$6MQ2 FY26

FY25$65.2B

Revenue

—

LLY1,407.25vsPRLD3.84Pre-marketNov 4 '26delayed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only PRLD 3

INCYIncytecustomer

ABCLAbCellera Biologicscustomer

—Pathos AIunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR